Insulet Co. (NASDAQ:PODD) has been assigned an average rating of “Hold” from the fifteen research firms that are presently covering the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $46.56.
A number of research firms have commented on PODD. BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a report on Monday, March 6th. Jefferies Group LLC reissued a “buy” rating and issued a $53.00 target price on shares of Insulet in a report on Thursday, April 13th. Robert W. Baird raised Insulet from a “neutral” rating to an “outperform” rating and raised their target price for the company from $39.00 to $47.00 in a report on Friday, January 6th. B. Riley reaffirmed a “neutral” rating and set a $44.00 price target on shares of Insulet in a research note on Monday, March 6th. Finally, Canaccord Genuity set a $39.00 price target on Insulet and gave the stock a “hold” rating in a research note on Monday, January 23rd.
In other Insulet news, Director David A. Lemoine sold 1,282 shares of Insulet stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $45.15, for a total value of $57,882.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Regina O. Sommer sold 40,000 shares of Insulet stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.00, for a total value of $1,800,000.00. The disclosure for this sale can be found here. Insiders sold a total of 81,282 shares of company stock valued at $3,732,282 in the last 90 days. 1.90% of the stock is owned by company insiders.
Shares of Insulet (NASDAQ:PODD) traded down 0.72% on Thursday, reaching $41.50. 555,367 shares of the company were exchanged. The stock’s market capitalization is $2.39 billion. The firm’s 50 day moving average price is $43.06 and its 200 day moving average price is $40.23. Insulet has a 52 week low of $26.50 and a 52 week high of $48.23.
Insulet (NASDAQ:PODD) last released its earnings results on Monday, February 27th. The medical instruments supplier reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.11. Insulet had a negative net margin of 12.95% and a negative return on equity of 87.46%. The business earned $103.58 million during the quarter, compared to analyst estimates of $100.61 million. During the same period last year, the business posted ($0.48) EPS. Insulet’s revenue was up 23.6% compared to the same quarter last year. Equities research analysts anticipate that Insulet will post ($0.44) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/04/22/insulet-co-podd-receives-46-56-consensus-price-target-from-brokerages.html.
About Insulet
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
